MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma multiforme [Multiforme MR perfusion og FLT- og FET-PET i løbet af Bevacizumab monoterapi for recidiverende Glioblastoma multiforme].
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2013
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Pharmacodynamics
- 09 Nov 2012 Planned number of patients changed from 32 to 16.
- 09 Nov 2012 Planned end date changed from 5 Jan 2013 to 5 Jan 2016 as reported by European Clinical Trials Database.
- 19 Jul 2012 New trial record